Company profile
Marker Therapeutics, Inc.
NASDAQ: MRKR · Healthcare · Biotechnology
#732 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
36DFH 40DQ 35GM 20SS 49
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ workforce scale, growth stability
Methodology →Revenue TTM
$2.1M
Rev growth YoY (TTM)
-63.2%
Net income (FY)
-$12.2M
Employees
5
as of 2026-08-21
Market cap
$20.3M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.5M$3.5M2025
Net income-$12.2M-$12.2M2025
Operating income-$12.9M-$12.9M2025
Total assets$19.1M$19.1M2025
Liabilities$2.3M$2.3M2025
Equity$16.8M$16.8M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Grant100%
By geography
Not disclosed.
The read
What is Marker Therapeutics, Inc.’s revenue?
Marker Therapeutics, Inc. booked $3.5M in FY2025 revenue, contracting 46% year over year — slower than 80% of Healthcare companies we track, at a -343.0% net margin.
Peers · Healthcare
Cibus, Inc.43DNeurAxis, Inc.45DRed Light Holland Corp.——Revitalist Lifestyle and Wellness Ltd.——SheerVision, Inc.——CAMP4 Therapeutics Corporation27DNeighbors
Harris →Key facts
CEOJuan F. Vera
SectorHealthcare
IndustryBiotechnology
HeadquartersHouston, TX
ExchangeNASDAQ: MRKR
Employees5
IPO date2002-07-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.